Chimeric Therapeutics Limited
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurre… Read more
Chimeric Therapeutics Limited (CHMMF) - Total Liabilities
Latest total liabilities as of June 2025: $19.60 Million USD
Based on the latest financial reports, Chimeric Therapeutics Limited (CHMMF) has total liabilities worth $19.60 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Chimeric Therapeutics Limited - Total Liabilities Trend (2020–2025)
This chart illustrates how Chimeric Therapeutics Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Chimeric Therapeutics Limited Competitors by Total Liabilities
The table below lists competitors of Chimeric Therapeutics Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bait Bakfar Ltd
TA:BKFR
|
Israel | ILA990.05 Million |
|
ALNYLAM PHARMA
MU:DUL
|
Germany | €4.17 Billion |
|
PT Sari Kreasi Boga Tbk
JK:RAFI
|
Indonesia | Rp185.32 Billion |
|
Libet S.A.
WAR:LBT
|
Poland | zł24.21 Million |
|
Meadow Valley Corp
PINK:MVCO
|
USA | $2.60 Million |
|
Mitra Angkasa Sejahtera PT Tbk
JK:BAUT
|
Indonesia | Rp55.98 Billion |
|
AIOS Tech Inc.
NASDAQ:AIOS
|
USA | $87.22 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Chimeric Therapeutics Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.72 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 9.92 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.91 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chimeric Therapeutics Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chimeric Therapeutics Limited (2020–2025)
The table below shows the annual total liabilities of Chimeric Therapeutics Limited from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $19.60 Million | +53.06% |
| 2024-06-30 | $12.80 Million | -23.40% |
| 2023-06-30 | $16.71 Million | +82.21% |
| 2022-06-30 | $9.17 Million | -19.35% |
| 2021-06-30 | $11.37 Million | +17670.20% |
| 2020-06-30 | $64.01K | -- |